The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods

Min-Sun Kwak1
Eunyoung Kim2
Eun Jin Jang3
Hyun Jung Kim4
Chang-Hoon Lee5

1Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea; 2Department of Statistics, Kyungpook National University, Daegu, Republic of Korea; 3Department of Information Statistics, Andong National University, Andong, Republic of Korea; 4Department of Preventive Medicine, College of Medicine, Korea University, Seoul, Republic of Korea; 5Department of Pulmonary and Critical Care Medicine, Division of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Correspondence: Chang-Hoon Lee
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul 110-744, Republic of Korea
Tel: +82 2 2072 4743
Fax: +82 2 762 9662
Email kauri670@empal.com

Purpose: Although tiotropium (TIO) and inhaled corticosteroid (ICS)/long-acting β-agonists are frequently prescribed together, the efficacy of “triple therapy” has not been scientifically demonstrated. We conducted a systematic review and meta-analysis using Bayesian methods to compare triple therapy and TIO monotherapy.

Methods: We searched the MEDLINE, EMBASE, and Cochrane Library databases for randomized controlled trials comparing the efficacy and safety of triple therapy and TIO monotherapy in patients with chronic obstructive pulmonary disease (COPD). We conducted a meta-analysis to compare the effectiveness and safety of triple therapy and TIO monotherapy using Bayesian random effects models.

Results: Seven trials were included, and the risk of bias in the majority of the studies was acceptable. There were no statistically significant differences in the incidence of death and acute exacerbation of disease in the triple therapy and TIO monotherapy groups. Triple therapy improved the prebronchodilator forced expiratory volume in 1 second (mean difference [MD], 63.68 mL; 95% credible interval [CrI], 45.29–82.73), and patients receiving triple therapy showed more improvement in St George Respiratory Questionnaire scores (MD, −3.11 points; 95% CrI, −6.00 to −0.80) than patients receiving TIO monotherapy. However, both of these differences were lower than the minimal clinically important difference (MCID). No excessive adverse effects were reported in triple therapy group.

Conclusion: Triple therapy with TIO and ICSs/long-acting β-agonists was only slightly more efficacious than TIO monotherapy in treating patients with COPD. Further investigations into the efficacy of new inhaled drugs are needed.

Keywords: inhaled long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICSs), inhaled long-acting β2-agonists (LABAs), chronic obstructive pulmonary disease (COPD)

Introduction
Inhaled drugs, including inhaled long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICSs), and inhaled long-acting β2-agonists (LABAs), are the principal therapeutic options for patients with chronic obstructive pulmonary disease (COPD). Until recently, tiotropium (TIO) was the only LAMA available, and it remains the most commonly used LAMA. Currently, these three classes of drugs (TIO, ICS, and LABA) are frequently prescribed together as “triple therapy”; however, there is insufficient scientific evidence demonstrating the efficacy of this combination. Only a few rigorous systematic reviews2,3 supporting the efficacy of triple therapy, including improvements in the health status of the patient and reductions in the future risk of the patient,1
have been published. In addition, these reviews have limitations. Only a few clinical trials have been conducted to investigate the benefits of triple therapy, and adverse outcomes, including death, are rarely reported in those studies. The assumption of normality, which may not hold for small studies, is necessary to construct confidence intervals, and continuity correction is required if there are zero events. Bayesian approaches to meta-analysis could overcome some of these issues. Moreover, Bayesian meta-analysis can provide a probabilistic interpretation of the treatment effect of interest and a probability of the effect being larger (or smaller) than a specific value. Bayesian meta-analysis can also be useful when evaluating whether the magnitude of efficacy is greater than the minimal clinically important difference (MCID). Thus, we conducted a systematic review using Bayesian methods to compare the efficacy and safety of triple therapy and TIO monotherapy.

Methods
To conduct this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the BayesWatch guidelines for reporting studies using Bayesian methods.

Data search and selection criteria
We searched the MEDLINE, EMBASE, and Cochrane Library databases (search date: November 2, 2014). The search terms were “COPD” AND “LAMA” AND (“ICS” AND “LABA”) OR ICS/LABA AND randomized protocol design. LAMAs included TIO, aclidinium, and glycopyrrolate. LABAs included salmeterol (SAL), formoterol (FOR), vilanterol, or indacaterol. ICSs included beclomethasone, budesonide (BUD), fluticasone propionate (FP), fluticasone furoate, triamcinolone, mometasone, and flunisolide. ICS/LABA combination drugs included FP/SAL, BUD/FOR, and fluticasone furoate/vilanterol. Additional details on our search strategy are provided in the Supplementary materials.

The study selection criteria were as follows: 1) randomized controlled trials (RCTs); 2) studies with adults aged ≥18 years and diagnosed with COPD; 3) studies comparing triple therapy with nontriple therapy; 4) trials lasting at least 4 weeks; 5) studies reporting at least one of the following outcomes: mortality, annual rate of decline of the forced expiratory volume in the first second (FEV₁), acute exacerbations, changes in prebronchodilator or trough FEV₁, changes in quality of life (St George Respiratory Questionnaire [SGRQ]), changes in the dyspnea scale using quantitative questionnaires (Chronic Respiratory Disease Questionnaire, Baseline/Transition Dyspnea Index, modified Medical Research Council, visual analog scale, numeric rating scale), and safety data (serious adverse events [SAE] and pneumonia); and 6) studies published in the English language. Studies with duplicate data were excluded.

Data extraction and assessment of risk of bias
Two authors (CHL and MSK) independently reviewed the titles, abstracts, and citations of the studies. After screening potentially relevant studies, they independently evaluated full reports for the eligibility based on the study design, intervention, and outcomes. The authors of five studies with missing required data were contacted to obtain additional information on outcomes; two of these authors provided the desired information. In studies with missing standard deviations for changes from baseline in continuous variables, we imputed standard deviations by calculating a correlation coefficient from a study for which we knew these details.

To assess the risk of bias of each study, the Cochrane risk of bias tool was applied. This assessment included the following: 1) the adequacy of sequence generation; 2) allocation concealment; 3) blinding of the participants, personnel, and outcome assessors; 4) incomplete outcome data; 5) selective outcome reporting; and 6) other biases. Any disagreements were resolved by discussion until a consensus was reached.

Statistical analysis
We used Bayesian random effects models to compare the efficacy and safety of triple therapy and TIO monotherapy. In these models, an assumption of normality and continuity correction factors are not required because these methods are well suited to small studies and rare events. We estimated the relative risk (RR) for the binary outcome data or the mean difference (MD) for continuous variables using the posterior mean and corresponding 95% credible interval (CrI), which is the Bayesian equivalent of a confidence interval in classical analyses. We calculated posterior probabilities of the RR being larger or smaller than 1 (denoted P(RR >1)) or P(RR <1), respectively). We also calculated posterior probabilities of the MD being larger or smaller than 0 (denoted P(MD >0) and P(MD <0), respectively). Additionally, we calculated Bayesian probabilities that the MD was greater than the MCID. The hypothesis of interest was supported if a posterior probability was greater than 0.9.
Inverse-gamma distributions, normal distributions with a mean of zero and large variance, and uniform distributions were considered noninformative priors for parameters. We used Review Manager 5.3 (Cochrane Collaboration, Oxford, UK), R 3.1.2 and WinBUGS 1.4 (Medical Research Council, Cambridge, and Imperial College School of Medicine, UK) software for our analyses. Three chains were considered to detect convergence. In each chain, the first 10,000 iterations were discarded to remove the influence of the initial value, and sampling from 10,000 additional iterations was used to generate summary statistics such as the posterior mean and 95% CrI. For certain analyses, every 10th or 30th number was extracted from the 10,000 samples to remove autocorrelations as needed. Gelman and Rubin statistics,21,22 Monte Carlo error, and autocorrelation plots were used to establish convergence of the Markov Chain Monte Carlo method. We performed sensitivity analyses to assess the impact of using different prior distributions. If the posterior median rather than the posterior mean of the between-study standard deviation was greater than one, then heterogeneity of the effects across studies was considered to exist, as the posterior mean is likely to have a skewed distribution. Publication bias was not formally assessed because each analysis included fewer than ten studies.23

Results
Figure 1 shows a flowchart describing our study selection process. Of 1,777 screened references, 39 studies were reviewed in further detail. Thirty-one of these studies were excluded for various reasons, including duplicate data, non-English language, and a short study duration. Finally, seven studies with a total of 2,122 subjects (triple therapy, n=1,052; TIO only, n=1,070) were included in this meta-analysis. The characteristics of the included studies are presented in Table 1. The duration of the studies ranged from 4 to 52 weeks, with most study durations ranging from 12 to 24 weeks. Four studies were sponsored by a pharmaceutical company. Most of the studies exhibited a low risk of bias according to the six bias assessment scores of the Cochrane Instrument.

Risk of bias within studies
Figure 2 shows a graph and summary of the risk of bias assessment. Most of the studies were judged to have a low risk of bias for random sequence generation, incomplete outcome data, and selective reporting. However, evaluations of allocation concealment and blinding of the participants, personnel and outcome assessors were limited, and some of the RCTs were judged to have a high or unclear risk of bias for these parameters.

Figure 1 Flowchart for the selection of studies.
Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trial; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.
Efficacy outcomes

In the three studies\(^\text{4,8,10}\) that reported the number of deaths, no statistically significant difference in mortality was found between the triple therapy group and the TIO monotherapy group (RR, 1.46; 95% CrI, 0.13–5.17; \(P\) (RR < 1) =0.47).

None of the studies reported rates of lung function decline. Four trials\(^\text{4,6,8,10}\) reported the number of acute exacerbations in patients receiving triple therapy or TIO monotherapy. We found that triple therapy provided a nonsignificant benefit in reducing the incidence of acute exacerbations.

---

Table 1 Included studies

| Authors            | RCT design | F/U weeks | Age\(^a\) | FEV\(_1\) %\(^a\) | Pack-years\(^a\) | Comparison | Primary outcome                      |
|--------------------|------------|-----------|-----------|------------------|-----------------|------------|-------------------------------------|
| Aaron et al\(^4\)  | Double-blind | 52        | 67.7      | 41.8             | 50.3            | TIO + FP (1,000 µg/d)/SAL (n=145) vs TIO (n=156) | Exacerbation of disease |
| Cazzola et al\(^5\) | Double-blind | 12        | 65.8      | 38.1             | 50.9            | TIO + FP (1,000 µg/d)/SAL (n=29) vs TIO (n=26) | Change in predose FEV\(_1\) |
| Welte et al\(^10\) | Double-blind | 12        | 62.5      | 37.9             | 37              | TIO + BUD (640 µg/d)/FOR (n=329) vs TIO (n=331) | Change in predose FEV\(_1\) |
| Hanania et al\(^6\) | Double-blind | 24        | 61.2      | 56.7             | 55.1            | TIO + FP (500 µg/d)/SAL (n=173) vs TIO (n=169) | Change in predose FEV\(_1\) |
| Jung et al\(^8\)   | Open-label  | 24        | 67.4      | 47.5             | NR              | TIO + FP (500 µg/d)/SAL (n=237) vs TIO (n=242) | Change in predose FEV\(_1\) |
| Hoshino and Ohtawa\(^7\) | Open-label | 16        | 71.2      | NR               | 57.7            | TIO + FP (500 µg/d)/SAL (n=15) vs TIO (n=15) | Airway dimension |
| Maltais et al\(^9\) | Double-blind | 4         | 62.7      | 54.7             | NR              | TIO + FP (500 µg/d)/SAL (n=124) vs TIO (n=131) | Exercise endurance time |

Note: \(^a\)Mean value.

Abbreviations: RCT, randomized controlled trial; TIO, tiotropium; FP, fluticasone propionate; SAL, salmeterol; BUD, budesonide; FOR, formoterol; NR, not recorded; F/U, follow-up; FEV\(_1\), forced expiratory volume in the first second.
(RR, 0.80; 95% CrI, 0.35–1.63; \(P (RR < 1) = 0.84\)). All of the trials investigating lung function reported a significant improvement in the prebronchodilator FEV\(_1\) in the patients receiving triple therapy, and the calculated pooled MD was 63.68 mL (95% CrI, 45.29–82.73) (\(P (MD > 0 \text{ mL}) = 1.0\)). However, the magnitude of this improvement was less than the MCID (100–140 mL)\(^{24}\) (\(P (MD > 100 \text{ mL}) = 0.002\)). The three studies\(^{4,8,10}\) evaluating the SGRQ score reported a significant improvement in the mean change from baseline in patients receiving triple therapy, with a difference of −3.11 points (95% CrI, −6.00 to −0.80; \(P (MD < 0 \text{ points}) = 0.99\)). However, the magnitude of this change was not over the MCID (−4.0)\(^{25}\) (\(P (MD < -4 \text{ points}) = 0.18\)) (Table 2 and Figure 3).

### Safety outcomes (adverse events)

Patients receiving triple therapy did not experience significantly more adverse events than patients receiving monotherapy (RR, 1.12; 95% CrI, 0.87–1.40; \(P (RR > 1) = 0.84\)). The total number of SAEs was significantly lower in the triple therapy group (RR, 0.62; 95% CrI, 0.17–1.25; \(P (RR < 1) = 0.93\)) than in the TIO monotherapy group. The risk of pneumonia was not significantly higher in the triple therapy group than in the TIO monotherapy group (RR, 1.07; 95% CrI, 0.05–4.28; \(P (RR > 1) = 0.27\)). The incidence of oral candidiasis was not significantly higher in the triple therapy group (RR, 3.63; 95% CrI, 0.46–12.82; \(P (RR > 1) = 0.88\)) (Table 3).

The posterior median of the between-study standard deviation in our meta-analysis was smaller than one, indicating a lack of heterogeneity. We did not find evidence against convergence, and we did not see any substantial differences. However, the CrI and probability changed slightly by changing the specifications of the prior distribution.

### Discussion

The goals of treating patients with COPD include improving the health status of the patient (lung function, quality of life, and exercise capacity) and decreasing future risks of acute exacerbation, lung function decline, and death.\(^1\) TIO is known to improve the quality of life and lung function of patients with COPD,\(^{26}\) reduce the likelihood of experiencing acute exacerbation,\(^{26–28}\) delay declines in lung function in patients with stage II disease,\(^{29}\) and possibly decrease mortality.\(^{30}\) ICS and LABAs are commonly used in combination in a single device (ICS/LABA). Large clinical trials showed that ICS/LABA combinations, including FP/SAL and BUD/FOR, improve the quality of life and lung function of patients with COPD,\(^{31–34}\) reduce the incidence of acute exacerbation,\(^{31–34}\) slow declines in lung function,\(^{35}\) and possibly reduce mortality.\(^{31}\) However, the efficacy and safety of triple therapy combining TIO and ICS/LABA have rarely been comprehensively investigated, especially in the context of accomplishing these treatment goals. As mentioned in the Introduction, a classical meta-analysis may not be adequate to evaluate the benefits of triple therapy. Because only a few clinical trials\(^{4–10}\) were conducted and rare events were included, the assumption of normality may not hold for the analysis. Therefore, we used Bayesian approaches to reduce some of these problems.\(^{11,12}\) Moreover, Bayesian meta-analysis can also be useful when evaluating whether the magnitude of efficacy is greater than the MCID\(^{14}\) by using posterior probabilities.\(^{12,13}\)

In our systematic review, we found limited evidence indicating that triple therapy can reduce future risks. Although we used Bayesian methods to analyze the incidence of rare events, we did not find that triple therapy reduced mortality to a greater extent than TIO monotherapy. None of the studies in our review investigated declines in lung function as an outcome. Additionally, we did not find that triple therapy significantly reduced the incidence of acute exacerbation (\(P (RR < 1) = 0.84\)). Welte et al\(^{36}\) reported that triple therapy produced a reduction in the incidence of acute exacerbation; however, this effect was not significantly different from that found by other studies in our meta-analysis.

---

**Table 2 Summary of efficacy outcomes**

| Outcome variable       | Number of studies | Total number of patients included | RR or MD (95% CrI) | Posterior probability | SD |
|------------------------|-------------------|----------------------------------|--------------------|-----------------------|----|
|                        |                   | Triple therapy | TIO monotherapy     |                      |    |
| Death\(^a\)            | 3                 | 705             | 725                 | 1.46 (0.13–5.17)     | \(P (RR < 1) = 0.47\) | 1.72 |
| Acute exacerbation\(^b\) | 4                | 870             | 888                 | 0.80 (0.35–1.63)     | \(P (RR < 1) = 0.84\) | 0.37 |
| Changes in FEV\(_1\) \(^b\) | 6           | 915             | 928                 | 0.80 (0.35–1.63)     | \(P (RR < 1) = 0.84\) | 0.37 |
| Changes in SGRQ\(^b\)  | 3                 | 697             | 711                 | 1.72 (1.12–2.58)     | \(P (MD > 0 \text{ mL}) = 1.0\) | 9.69 |

**Notes:** RR for binary outcomes, MD for continuous outcomes. Abbreviations: FEV\(_1\), forced expiratory volume in the first second; TIO, tiotropium; SGRQ, St George Respiratory Questionnaire; RR, relative risk; CrI, credible interval; MD, mean difference; SD, standard deviation (between studies).
One interpretation of these findings is that the BUD/FOR combination is more efficacious than the FP/SAL combination; alternatively, these findings could be explained by the short duration of the trial (only 12 weeks). The mitigation in acute exacerbation could be observed only for a short duration. The three other trials lasted at least 24 weeks.

The present results indicate that triple therapy improves the health status of patients with COPD; however, the improvements achieved were lower in magnitude than the

![Table 3 Summary of adverse events](https://www.dovepress.com/t03-summary-of-adverse-events.pdf)

| Outcome                  | Number of studies | Total number of patients included | RR (95% CrI) | Posterior probability | SD       |
|--------------------------|-------------------|-----------------------------------|--------------|-----------------------|----------|
| Total adverse events     | 5                 | 800                               | 1.12 (0.87–1.40) | P (RR > 1) = 0.84     | 0.14     |
| Severe adverse events    | 6                 | 1,031                             | 0.62 (0.17–1.25) | P (RR < 1) = 0.93     | 0.29     |
| Pneumonia                | 4                 | 829                               | 1.07 (0.05–4.28) | P (RR > 1) = 0.27     | 3.63     |
| Oral candidiasis         | 3                 | 647                               | 3.63 (0.46–12.82) | P (RR > 1) = 0.88     | 4.53     |

Abbreviations: TIO, tiotropium; RR, relative risk; CrI, credible interval; SD, standard deviation (between studies).
MCID. All of the trials investigating lung function reported significant improvements in the prebronchodilator FEV$_1$; however, the increase in FEV$_1$ was lower in magnitude than the MCID (100 mL) ($P$ [MD $>$ 100 mL] = 0.002). $^{24}$ Triple therapy also improved SGRQ scores; however, the magnitude of improvement was lower than the MCID $^{25}$ ($P$ [MD $<$ −4.0 points [MCID]] = 0.18). Thus, triple therapy can marginally improve the prebronchodilator FEV$_1$ and SGRQ scores of patients with COPD.

There are several possible explanations for the marginal difference in efficacy between triple therapy and TIO monotherapy. First, even though we used Bayesian methods, we were able to identify only a few trials, which could suggest the existence of bias. Second, the definition of acute exacerbation varied between trials. Third, TIO monotherapy is known to be efficacious; therefore, a ceiling effect may exist, and combining TIO with other inhaled drugs may not confer additional or synergistic effects. TIO is considered to be the most effective bronchodilator. TIO is superior to most LABAs in reducing the incidence of acute exacerbation, $^{36,37}$ including indacaterol, a new LABA. $^{38}$ TIO is also superior or at least equivalent to LABAs in improving the FEV$_1$ and SGRQ scores. Certain studies have reported that indacaterol is superior to TIO in improving the FEV$_1$; however, this finding was not confirmed in a large-scale trial or in the trial sponsored by the manufacturer of indacaterol. $^{39}$ Furthermore, no studies using indacaterol were included in our systematic review because they lacked a triple therapy group. In fact, TIO monotherapy has been shown to be as effective as TIO + LABA dual therapy. Several RCTs $^{40,41}$ and a meta-analysis $^{42}$ showed no significant differences in the incidence of acute exacerbation in patients receiving TIO monotherapy and patients receiving a combination of TIO and LABAs. Although TIO + LABA dual therapy has been reported to be superior to TIO monotherapy in improving the FEV$_1$ and SGRQ scores, $^{43}$ the MDs encountered in our analysis were lower than the MCID.

We found no clear evidence that triple therapy is significantly more efficacious in improving the health status of the patient and reducing future risks; however, triple therapy was also not associated with an increased incidence of adverse events. The total number of adverse events was nonsignificantly higher in the ICS/LABA + TIO group than in the TIO monotherapy group. However, significantly fewer SAEs occurred in the triple therapy group than in the TIO monotherapy group. Pneumonia, a critical possible adverse event in patients using ICS, $^{31,42,43}$ was not found to occur more often in any particular group in this systematic review. Additionally, patients in the triple therapy group were not significantly more likely to experience oral candidiasis.

Our study has several strengths. First, the Bayesian methods we used are more appropriate for analyzing rare events and for assessing a small number of studies. Second, we could evaluate whether the effect of interest was greater than the MCID because Bayesian meta-analysis can provide a probability that the effect is larger (or smaller) than a specific value, which was overlooked in previous meta-analyses. $^{12}$ We also acknowledge the limitations of our systematic review. First of all, studies have different study durations, which could lead to biased results. Inclusion of COPD patients with wide-range severity might also be a weak point, because mortality, lung function decline, and exacerbation can be affected by FEV$_1$ of patients. $^{44-46}$ We initially intended to compare triple therapy and dual therapies; however, it was impossible to do so because no common outcomes were described in the available studies. We also attempted to include studies evaluating new ICSs, LABAs, and LAMAs; however, no studies compared these therapies with triple therapy. Additionally, we were not always able to obtain more detailed clinical information when contacting authors by email.

Conclusion

In conclusion, our systematic review using Bayesian meta-analysis showed that triple therapy with TIO and ICS/LABA was more efficacious than TIO monotherapy. However, the increase in efficacy was marginal, and the clinical relevance of the improvement was unclear. Further investigations evaluating new bronchodilators are needed.

Acknowledgment

Seoul National University Hospital Research Fund (2320130040 (2013-2423)).

Author contributions

CHL and MSK: conception and design of the study, selection of study, independent assessment of risk of bias, extraction, analysis, interpretation of the data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and final approval of the manuscript. HJK, EJJ, and EK: design of the study, selection of studies, analysis of data, interpretation of the data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.
References

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2014. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed September 19, 2015.

2. Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med. 2014;25(5):491–495.

3. Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012;25(1):40–47.

4. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.

5. Cazzola M, Ando F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007;20(5):556–561.

6. Hanania NA, Crater GD, Morris AN, Emmett AH, O’Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol with tiotropium to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101.

7. Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration. 2013;86(4):280–287.

8. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382–389.

9. Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J. 2013;42(2):539–541.

10. Welte T, Miravitles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–750.

11. Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ. Meta-analysis of rare and adverse event data. Exp Rev Pharmacoecon Outcomes Res. 2002;2(4):367–379.

12. National Evidence-based Healthcare Collaborating Agency. Bayesian Meta-Analysis Method. Seoul, Korea: NECA; 2013.

13. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Hoboken, NJ: Wiley; 2000.

14. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66(2):173–183.

15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–W94.

16. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000; 4(38):1–130. 30.

17. Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane collaboration; 2011.

18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

19. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med. 2002;21(11):1601–1623.

20. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 2008;336(7651):1006–1009.

21. Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457–511.

22. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1997;7:434–455.

23. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–1129.

24. Martinez FJ, Donohue JF, Renard SI. The future of chronic obstructive pulmonary disease treatment – difficulties of and barriers to drug development. Lancet. 2011;378(9795):1027–1037.

25. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79.

26. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.

27. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317–326.

28. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006;27(3):547–555.

29. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178.

30. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955.

31. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.

32. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.

33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.

34. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2008;32(6):912–919.

35. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338.

36. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364(12):1093–1103.

37. Chong J, Kerner C, Poole P. Tiotropium versus long-acting β2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.

38. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.

39. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McIlroy S. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2013;107(2):223–232.

40. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511–1520.

41. Kerner C, Cates CJ. Long-acting β(2)-agonist in addition to tiotropium versus either tiotropium or long-acting β(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;4:CD008989.

42. Lee CH, Jang EJ, Hyun MK, Lee NR, Kim K, Yim JJ. Risk of hospital admission or emergency room visit for pneumonia in patients using respiratory inhalers: a case-crossover study. Respirology. 2013;18(7):1116–1127.
43. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database of Syst Rev*. 2014;3:CD010115.

44. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350(10):1005–1012.

45. Tantucci C, Modina D. Lung function decline in COPD. *Int J Chron Obstruct Pulm Dis*. 2012;7:95–99.

46. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010;363(12):1128–1138.
Supplementary materials
Details of the search strategy.

MEDLINE
1. (“Lung Diseases, Obstructive”[Mesh:noexp] OR “Pulmonary Disease, Chronic Obstructive”[Mesh] OR “Pulmonary Emphysema”[Mesh]) OR (“Chronic obstructive pulmonary disease”[TIAB] OR “Emphysema”[TIAB] OR “Chronic bronchitis”[TIAB] OR “Chronic obstructive lung disease”[TIAB] OR “Obstructive lung disease”[TIAB] OR “Obstructive pulmonary disease”[TIAB] OR “Obstructive lung diseases”[TIAB] OR “Obstructive pulmonary diseases”[TIAB] OR “COPD”[TIAB]) 79230
2. ((((((((((groups[tiab]) OR (trial[tiab]) OR (randomly[tiab]) OR (drug therapy[sh]) OR (placebo[tiab]) OR (randomized[tiab]) OR (controlled clinical trial[pt]))) OR (randomized controlled trial[pt]))) NOT (animals[Mesh] NOT (humans[Mesh] AND animals[Mesh]))) 2865448
3. (((((“Indans/administration and dosage”[Mesh:noexp] OR “Indans/pharmacology”[Mesh:noexp] OR “Indans/therapeutic use”[Mesh:noexp]) OR (“Quinolones/administration and dosage”[Mesh:noexp] OR “Quinolones/adverse effects”[Mesh:noexp] OR “Quinolones/pharmacology”[Mesh:noexp] OR “Quinolones/therapeutic use”[Mesh:noexp]) OR (“5-(2-(5, 6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one”[Supplementary Concept]) OR (“onbrez”[tiab] OR “indacaterol”[TIAB]) OR (“adrenergic beta-2 receptor agonists”[MeSH Terms])) 11230
4. (“ICS”[TIAB]) OR (((“Bronchodilator Agents/administration and dosage”[Mesh] OR “Bronchodilator Agents/adverse effects”[Mesh]) OR “Bronchodilator Agents/therapeutic use”[Mesh]) OR (“Bronchodilator Agents/toxicity”[Mesh])) OR (((inha1*) AND (Corticosteroid* OR cortico-steroid* OR beclomethasone[tiab] OR beclazone[tiab] OR becotide[tiab] OR becloforte[tiab] OR budesonide[tiab] OR pulmicort* OR fluticasone[tiab] OR flouxotide[tiab] OR qvar[tiab] OR filair[tiab] OR aerobec[tiab] OR asmabec[tiab] OR becodisk* OR triamcinolone[tiab] OR mometasone[tiab] OR flunisolide[tiab])) OR (“Adrenal Cortex Hormones/administration and dosage”[Mesh] OR “Adrenal Cortex Hormones/adverse effects”[Mesh] OR “Adrenal Cortex Hormones/therapeutic use”[Mesh] OR “Adrenal Cortex Hormones/toxicity”[Mesh]))) 101754
5. (((“fluticasone furoate”[Supplementary Concept] OR “fluticasone furoate”[tiab]) AND (“vilanterol”[Supplementary Concept] OR “vilanterol”[tiab]) OR “fluticasone furoate/vilanterol”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab])) OR ((((((“fluticasone”[Supplementary Concept] OR “fluticasone”[TIAB]) AND (“drug combinations”[MeSH] OR (“drug”[TIAB] AND “combinations”[TIAB]) OR “drug combinations”[TIAB] OR (“drug”[TIAB] AND “combination”[TIAB]) OR (“drug”[TIAB] AND “combination”[TIAB]) OR “drug combination”[TIAB])))) OR (“budesonide”[MeSH Terms] OR “budesonide”[TIAB] AND (“formoterol”[Supplementary Concept] OR “formoterol”[TIAB]) AND (“drug combinations”[MeSH] OR (“drug”[TIAB] AND “combinations”[TIAB]) OR “drug combinations”[TIAB] OR (“drug”[TIAB] AND “combination”[TIAB]) OR (“drug”[TIAB] AND “combination”[TIAB]) OR “drug combination”[TIAB]))) OR (“fluticasone, salmeterol drug combination”[Supplementary Concept] OR “fluticasone/salmeterol”[tiab] OR “Fluticasone-salmeterol combination”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab] OR “Fluticasone furoate-vilanterol combination”[tiab]) OR (((“adrenergic beta-2 receptor agonists”[MeSH] OR “bronchodilator agents”[MeSH]) AND “drug combinations”[MeSH]))) AND (“Adrenal Cortex Hormones”[MeSH] OR “Anti-Asthmatic Agents”[MeSH])) 8692
6. (((((“long-acting muscarinic antagonist”[TIAB] OR “LAMA”[TIAB]) OR (“Spiriva”[TIAB] OR “tiotropium”[TIAB]))) OR (((“Cholinergic Antagonists/administration and dosage”[Mesh] OR “Cholinergic Antagonists/adverse effects”[Mesh] OR “Cholinergic Antagonists/pharmacology”[Mesh] OR “Cholinergic Antagonists/therapeutic use”[Mesh]) OR “Cholinergic Antagonists/toxicity”[Mesh]))) OR (“Scopolamine Derivatives/administration and dosage”[Mesh] OR “Scopolamine Derivatives/adverse effects”[Mesh] OR “Scopolamine Derivatives/pharmacology”[Mesh] OR “Scopolamine Derivatives/therapeutic use”[Mesh] OR “Scopolamine Derivatives/toxicity”[Mesh]))) OR (“Muscarinic Antagonists/administration and dosage”[Mesh] OR “Muscarinic Antagonists/adverse effects”[Mesh] OR “Muscarinic Antagonists/pharmacology”[Mesh] OR “Muscarinic Antagonists/therapeutic use”[Mesh]) 1075
OR “Muscarinic Antagonists/therapeutic use”[Mesh] OR “Muscarinic Antagonists/toxicity”[Mesh]) OR (“tiotropium”[Supplementary Concept]) OR (((“Glycopyrronium Bromide”[tiab] OR “aclidinium bromide”[tiab]) OR (((“aclidinium bromide”[Supplementary Concept]) OR “Glycopyrrolate”[Mesh])) 17656

7. 1 AND (3 AND 4) OR 5) AND 6) 1324

8. 7 AND 2 1123

EMBASE

1. ‘momentasone’:ab, ti OR ‘ics’:ab, ti OR ‘inhaled corticosteroid’:ab, ti OR ‘budesonide’:ab, ti OR ‘glucocorticoids’:ab, ti OR ‘adrenal cortex hormones’:ab, ti OR ‘corticosteroids’:ab, ti OR ‘pulmicort’:ab, ti OR ‘horacort’:ab, ti OR ‘rhinocort’:ab, ti OR ‘volon’:ab, ti OR ‘aristocort’:ab, ti OR ‘glucocorticoid’:ab, ti OR ‘beclometasone’:ab, ti OR ‘flunisolide’:ab, ti OR ‘beclometasone’:ab, ti OR ‘asmaclab clickhaler’:ab, ti OR ‘asococortonyl’:ab, ti OR ‘beclamet’:ab, ti OR ‘beclomet’:ab, ti OR ‘bemedrex easyhaler’:ab, ti OR ‘beclorhinol’:ab, ti OR ‘becloturmant’:ab, ti OR ‘sanasthmax’:ab, ti OR ‘beclovent’:ab, ti OR ‘beconase’:ab, ti OR ‘becloforte’:ab, ti OR ‘becodisk’:ab, ti OR ‘becotide’:ab, ti OR ‘propademi’:ab, ti OR ‘sanasthmyn’:ab, ti OR ‘becodisks’:ab, ti OR ‘bronchocort’:ab, ti OR ‘junik’:ab, ti OR ‘qvar’:ab, ti OR ‘aerobec’:ab, ti OR ‘beclazone’:ab, ti OR ‘ecobec’:ab, ti OR ‘filair’:ab, ti OR ‘nasobec aqueous’:ab, ti OR ‘polarair’:ab, ti OR ‘respocort’:ab, ti OR ‘ventolair’:ab, ti OR ‘vancenase’:ab, ti OR ‘aldecin’:ab, ti OR ‘viarin’:ab, ti 144077

2. ‘glucocorticoid’/exp OR ‘corticosteroid’/exp OR ‘steroid’/exp OR ‘pregnane derivative’/exp OR ‘androstan derivative’/exp NOT (“hydroxycorticosteroid”/exp OR “mineralocorticoid”/exp) 1254293

3. 1 OR 2 1280780

4. ‘onbrez’/exp OR ‘onbrez’:ab, ti 607

5. ‘beta 2 adrenergic receptor stimulating agent’/exp OR ‘beta 2 adrenergic receptor stimulating agent’:ab, ti 10767

6. ‘indacaterol’/exp OR ‘indacaterol’:ab, ti 317

7. 4-6/11198

8. 3 AND 7 7917

9. (‘corticosteroid’/exp OR ‘antiasthmatic agent’/exp) AND (‘beta 2 adrenergic receptor stimulating agent’/exp OR ‘bronchodilating agent’/exp) AND ‘drug combination’/exp 1879

10. ‘fluticasone propionate plus salmeterol’/exp OR ‘fluticasone propionate plus salmeterol xinafoate’/exp OR ‘seretide’:ab, ti OR ‘androstane derivative’/exp OR ‘budesonide plus formoterol’/exp OR ‘budesonide plus formoterol fumarate’/exp OR ‘symbicort’:ab, ti OR ‘fluticasone/salmeterol’:ab, ti OR ‘budesonide/formoterol’:ab, ti 7345

11. ‘fluticasone furoate plus vilanterol’/exp OR ‘fluticasone propionate plus salmeterol’/exp OR ‘budesonide plus formoterol’/exp 2984

12. 9–11/10 8942

13. 8 OR 12 15898

14. ‘cholinergic receptor blocking agent’/exp OR ‘scopolamine derivative’/exp OR ‘muscarinic receptor blocking agent’/exp OR ‘tiotropium bromide’/exp 150859

15. ‘spiriva’:ab, ti OR ‘tiotropium’:ab, ti OR ‘lama’:ab, ti OR ‘long-acting muscarinic antagonist’:ab, ti 2268

16. ‘aclidinium bromide’/exp OR ‘glycopyrronium bromide’/exp 4527

17. ‘aclidinium bromide’:ab, ti OR ‘glycopyrronium bromide’:ab, ti 177

18. 14–17/10 151653

19. 13 AND 18 3997

20. ‘emphysema’/exp OR ‘emphysema’ OR ‘emphysema’:ab, ti OR ‘chronic bronchitis’/exp OR ‘chronic bronchitis’ OR ‘chronic bronchitis’:ab, ti OR ‘obstructive lung disease’/exp OR ‘obstructive lung disease’ OR ‘obstructive lung disease’:ab, ti OR ‘obstructive pulmonary disease’/exp OR ‘obstructive pulmonary disease’ OR ‘obstructive pulmonary disease’:ab, ti OR ‘obstructive lung diseases’:ab, ti OR ‘chronic obstructive lung disease’/exp OR ‘chronic obstructive lung disease’ OR ‘chronic obstructive lung disease’:ab, ti 125588

21. 19 AND 20 2073

22. ‘crossover procedure’/exp OR ‘crossover procedure’ OR ‘double blind procedure’/exp OR ‘double blind procedure’ OR ‘randomized controlled trial’/exp OR ‘randomized controlled trial’ OR ‘single blind procedure’/exp OR ‘single blind procedure’ OR ‘random* OR factorial* OR crossover* OR ‘cross over’ OR ‘crossover’ OR placebo* OR (doub* AND blind*) OR (sing!*
COCHRANE
1. ICS:ti, ab, kw (Word variations have been searched) 694
2. MeSH descriptor: [Bronchodilator Agents] explode all trees and with qualifier(s): [Administration and dosage – AD, Adverse effects – AE, Therapeutic use – TU, Toxicity – TO] 3009
3. (inha*) and (Corticosteroid* or cortico-steroid* or beclomethasone or beclazone or becotide or beclolorte or budesonide or pulmicort* or fluticasone or flixotide or qvar or filair or aerobec or asmabec or becodisk* or triamcinolone or mometasone or flunisolide):ti, ab, kw (Word variations have been searched) 5191
4. MeSH descriptor: [Adrenal Cortex Hormones] explode all trees and with qualifier(s): [Administration and dosage – AD, Adverse effects – AE, Therapeutic use – TU, Toxicity – TO] 5220
5. 1–4/or 11759
6. onbrez or indacaterol:ti, ab, kw (Word variations have been searched) 141
7. adrenergic beta-2 receptor agonists 87
8. #6 or #7 277
9. (fluticasone):ti, ab, kw and (salmeterol):ti, ab, kw 965
10. (formoterol):ti, ab, kw and (budesonide):ti, ab, kw 643
11. (seretide):ti, ab, kw or (symbicort):ti, ab, kw or (fluticasone salmeterol):ti, ab, kw or (budesonide formoterol):ti, ab, kw 1557
12. MeSH descriptor: [Drug Combinations] explode all trees 9258
13. fluticasone furoate plus vilanterol:ti, ab, kw (Word variations have been searched) 1
14. MeSH descriptor Cholinergic Antagonists explode all trees 879
15. MeSH descriptor Scopolamine Derivatives explode all trees 868
16. MeSH descriptor Muscarinic Antagonists explode all trees 575
17. (spiriva):ab, ti OR (tiotropium):ab, ti OR (lama):ab, ti OR (long-acting muscarinic antagonist):ab, ti 629
18. “glycopyrronium bromide” or “aclidinium bromide”: ti, ab, kw (Word variations have been searched) 239
19. MeSH descriptor Emphysema explode all trees 97
20. emphysema:ti, ab, kw OR chronic bronchitis:ti, ab, kw OR chronic obstructive lung disease:ti, ab, kw OR obstructive lung disease:ti, ab, kw OR obstructive pulmonary disease:ti, ab, kw 813
21. COPD:ti, ab, kw 6441
22. MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees 2349
23. (#19 OR #20 OR #21 OR #22) AND ((#5 AND #8) OR (#9 OR #10 OR #11 OR #12 OR #13)) AND (#14 OR #15 OR #16 OR #17 OR #18) 84